Some technical considerations in planning for health

1972 ◽  
Vol 1 (2) ◽  
pp. 149-161 ◽  
Author(s):  
Peter Draper
Keyword(s):  
United States ◽  
Health Care ◽  
National Health Service ◽  
Health Service ◽  
Gross National Product ◽  
General Pattern ◽  
The United States ◽  
Industrialized Countries ◽  
The United Kingdom ◽  
Technical Considerations

Even in Western industrialized countries which have for several decades spent around 5 per cent of their Gross National Product on health care, interest in planning for health is recent. In countries like the United States, with what is sometimes described as a pluralist system, this is scarcely surprising. When the United States is described more bluntly, as it was for example by Walter Reuther, the incompatibility of planning with the general pattern of delivery is clear: ‘What we have, in fact, is a disorganized, disjointed, antiquated, obsolete, non-system of health care.’ But even in the United Kingdom with the framework for planning provided by the National Health Service, observers have been struck by the failure to develop an adequate planning mechanism in twenty years. This view has not been confined to foreign observers nor to British commentators outside the medical establishment.

Health Systems in the United Kingdom and Their Role in Increasing Equity

PEDIATRICS ◽  
2003 ◽  
Vol 112 (Supplement_3) ◽  
pp. 716-720
Author(s):  
Leslie Davidson
Keyword(s):  
United States ◽  
Health Care ◽  
United Kingdom ◽  
National Health Service ◽  
Health Service ◽  
The United States ◽  
Personal Reflection ◽  
Levels Of Care ◽  
The United Kingdom ◽  
The Uk

The Issue. This article describes the organization of the National Health Service with respect to the primary and secondary levels of care it offers children. It begins with a personal reflection from 17 years ago that is still relevant to the challenges confronting families in the United Kingdom today. It will discuss the basics of what is different and what is similar when comparing the UK health care system to that of the United States.

Loudness intensity and tinnitus frequency

1984 ◽  
Vol 98 (S9) ◽  
pp. 67-68
Author(s):  
E. Douek
Keyword(s):  
United States ◽  
United Kingdom ◽  
National Health Service ◽  
Health Service ◽  
National Health ◽  
The United States ◽  
Point Of View ◽  
The United Kingdom ◽  
Lump Sum

What I have to say follows on very naturally from what Dr. Johnson has just said. I ought to explain that in the United Kingdom we work in somewhat different situations from yours in the United States, from the administrative point of view, but most particularly from the financial funding point of view. Under the National Health Service we are not paid per item of service; we get a lump sum on which we have to run our departments. If we see two patients or if we see a million patients it makes no difference. In many ways, if we see few patients we can give them a better service than if we see many. I realise that this is a concept which is perhaps new to those of you in the United States, that your income in fact comes from numbers of patients.

Denial of Health Care and Informed Consent in English and American Law

1992 ◽  
Vol 18 (1-2) ◽  
pp. 37-71
Author(s):  
Frances H. Miller
Keyword(s):  
United States ◽  
Health Care ◽  
Informed Consent ◽  
The United States ◽  
Health Care Rationing ◽  
Legal Obligation ◽  
The United Kingdom ◽  
American Law ◽  
Care Rationing ◽  
Increased Pressure

Health care rationing has gained greater visibility in the United States and the United Kingdom, for quite different reasons. As patients in both countries become more aware that potentially beneficial medical services can be denied them on economic — as opposed to purely medical — grounds, they are beginning to seek help from the judiciary. This Article contends that as rationing becomes more explicit, the doctrine of informed consent will come under increased pressure. The Article suggests that courts and legislatures consider imposing a legal obligation on physicians to inform their patients when potentially effective treatment is to be withheld for economic or other non-clinical reasons.

The U.S. Health Delivery System: Inefficient and Unfair to Children

1997 ◽  
Vol 23 (2-3) ◽  
pp. 319-337
Author(s):  
Loretta M. Kopelman ◽  
Michael G. Palumbo
Keyword(s):  
United States ◽  
Health Care ◽  
Universal Access ◽  
The United States ◽  
Industrialized Countries ◽  
Health Care Resources ◽  
Health Delivery ◽  
Hip Replacements ◽  
The Many ◽  
Older Citizens

What proportion of health care resources should go to programs likely to benefit older citizens, such as treatments for Alzheimer’s disease and hip replacements, and what share should be given to programs likely to benefit the young, such as prenatal and neonatal care? What portion should go to rare but severe diseases that plague the few, or to common, easily correctable illnesses that afflict the many? What percentage of funds should go to research, rehabilitation or to intensive care? Many nations have made such hard choices about how to use their limited funds for health care by explicitly setting priorities based on their social commitments. In the United States, however, allocation of health care resources has largely been left to personal choice and market forces. Although the United States spends around 14% of its gross national product (GNP) on health care, the United States and South Africa are the only two industrialized countries that fail to provide citizens with universal access.

scholarly journals South Asian Heroes

2020 ◽  
Vol 13 (3) ◽  
Author(s):  
Triya Chakravorty
Keyword(s):  
Health Care ◽  
National Health Service ◽  
Health Service ◽  
South Asian ◽  
Health Care Workers ◽  
Asian Origin ◽  
South Asian Origin ◽  
The United Kingdom ◽  
Care Workers ◽  
Research And Education

The United Kingdom National Health Service (NHS) staff and students have been working tirelessly throughout the pandemic in a multitude of ways, including caring for patients, volunteering their time, or being involved in research and education. People of Asian origin make up 29.7% of the NHS medical workforce1. In recognition of South Asian Heritage Month, we asked our readers to nominate health care workers of South Asian origin who have demonstrated their tenacity, innovation, and excellence in recent months.

scholarly journals Cancer Drugs: An International Comparison of Postlicensing Price Inflation

2017 ◽  
Vol 13 (6) ◽  
pp. e538-e542 ◽  
Author(s):  
Philip Savage ◽  
Sarah Mahmoud ◽  
Yogin Patel ◽  
Hagop Kantarjian
Keyword(s):  
United States ◽  
Health Care ◽  
United Kingdom ◽  
The United States ◽  
Cancer Drug ◽  
Cancer Drugs ◽  
Price Inflation ◽  
Drug Prices ◽  
The United Kingdom ◽  
Price Increases

Purpose: The cost of cancer drugs forms a rising proportion of health care budgets worldwide. A number of studies have examined international comparisons of initial cost, but there is little work on postlicensing price increases. To examine this, we compared cancer drug prices at initial sale and subsequent price inflation in the United States and United Kingdom and also reviewed relevant price control mechanisms. Methods: The 10 top-selling cancer drugs were selected, and their prices at initial launch and in 2015 were compared. Standard nondiscounted prices were obtained from the relevant annual copies of the RED BOOK and the British National Formulary. Results: At initial marketing, prices were on average 42% higher in the United States than in the United Kingdom. After licensing in the United States, all 10 drugs had price rises averaging an overall annual 8.8% (range, 1.4% to 24.1%) increase. In comparison, in the United Kingdom, six drugs had unchanged prices, two had decreased prices, and two had modest price increases. The overall annual increase in the United Kingdom was 0.24%. Conclusion: Cancer drug prices are rising substantially, both at their initial marketing price and, in the United States, at postlicensing prices. In the United Kingdom, the Pharmaceutical Price Regulation Scheme, an agreement between the government and the pharmaceutical industry, controls health care costs while allowing a return on investment and funds for research. The increasing costs of cancer drugs are approaching the limits of sustainability, and a similar government-industry agreement may allow stability for both health care provision and the pharmaceutical industry in the United States.

Sign in / Sign up

Export Citation Format

Share Document